Kodiak Sciences (NASDAQ:KOD) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $3.00 price target on the stock.

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Monday, December 9th.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $2.81 on Monday. The stock’s 50 day moving average price is $4.76 and its 200 day moving average price is $5.45. The firm has a market capitalization of $147.87 million, a PE ratio of -0.77 and a beta of 2.26. Kodiak Sciences has a one year low of $2.19 and a one year high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.06. On average, analysts forecast that Kodiak Sciences will post -3.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

Large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in shares of Kodiak Sciences by 26.4% during the third quarter. FMR LLC now owns 200,971 shares of the company’s stock valued at $525,000 after acquiring an additional 41,987 shares during the period. State Street Corp grew its position in Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after purchasing an additional 14,711 shares during the last quarter. Barclays PLC grew its position in Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after purchasing an additional 31,527 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after purchasing an additional 12,783 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.